Spyre Therapeutics Expects To Report That It Had ~$741M Of Cash, Cash Equivalents And Marketable Securities As Of March 31, 2026; Suspends And Terminates ATM Prospectus For At-The-market Offering Effective April 13, 2026
Item 2.02 Results of Operations and Financial Condition.On April 13, 2026, Spyre Therapeutics, Inc. (the "Company") announced that while the Company has not finalized its full financial
